Radical Numerics Raises $50M for Biological AI
Key insights
- Radical Numerics raised $50M led by Emergence Capital to build multimodal AI learning simultaneously from DNA, RNA, and protein data.
- Their Omnii model achieves state-of-the-art results identifying causal regulatory variants, targeting cancer diagnostics and biosecurity applications.
- Former U.S. assistant secretary of defense Andrew Weber joins the advisory board, signaling early defense-sector engagement with biological AI.
Why this matters
Moving from single-modality genomics AI to simultaneous DNA, RNA, and protein learning mirrors the architectural shift that produced major capability jumps in multimodal vision-language models, suggesting biological AI could see similar step-change improvements in predictive power. The explicit dual-use acknowledgment from CEO Eric Nguyen at launch, backed by former U.S. assistant secretary of defense Andrew Weber on the advisory board, signals that biological AI companies will face national security scrutiny that most AI startups have never had to navigate. Patrick Collison's pre-seed involvement and Emergence Capital's lead set a fundraising and credibility benchmark that will pressure competitors in biological AI to articulate both technical differentiation and biosecurity governance from day one.
Summary
Radical Numerics launched from stealth with a $50 million seed round, led by Emergence Capital, to build what it calls 'general biological intelligence': AI systems that learn from DNA, RNA, and protein data simultaneously rather than one modality at a time.
The founding team, led by CEO Eric Nguyen, previously built Evo and Evo 2, DNA-reading and writing models that appeared on the covers of both Science and Nature. Their new model Omnii is a next-generation genomic language model showing state-of-the-art results in identifying causal regulatory variants, with applications in cancer diagnostics, drug target identification, and biosecurity.
Essentially: (Radical Numerics, Emergence Capital, Patrick Collison) are betting that multimodal biological AI unlocks capabilities single-modality genomics cannot reach.
- The team already generated the first complete AI-designed genome, a bacteriophage, before this launch.
- Scientific advisors include Microsoft CSO Eric Horvitz, Harvard geneticist George Church, and former U.S. assistant secretary of defense Andrew Weber.
- CEO Eric Nguyen: 'The same models that can help cure disease may also lower the barrier to designing harmful biology.'
That dual-use framing is positioned as a founding obligation, not an afterthought, with a defense-world advisor already at the table.
Potential risks and opportunities
Risks
- If Omnii's biological sequence design capabilities advance faster than biosecurity frameworks, federal agencies such as NIH or DHS could impose access restrictions before the company's cancer diagnostic and drug target applications reach clinical use.
- High-profile advisors including Harvard geneticist George Church and Microsoft CSO Eric Horvitz face reputational exposure if a dual-use incident occurs, potentially chilling future academic participation in biological AI ventures.
- Existing biological AI competitors face pressure to match multimodal DNA-RNA-protein architectures with less capital than Radical Numerics' $50M seed, potentially accelerating deployments without equivalent safety review.
Opportunities
- Biosecurity contractors and defense-adjacent firms gain leverage pitching biological AI monitoring tools to government clients, given Radical Numerics' explicit dual-use framing normalizing the risk category at the company's founding.
- Cancer centers and hospital systems with large multi-omics datasets become high-value strategic partners for Omnii's pancreatic and multi-cancer detection applications.
- Co-investors Obvious Ventures, Triatomic Capital, Factory, and First Spark Ventures are positioned for outsized returns if Omnii's benchmarks hold through clinical validation, setting a valuation floor for serious biological AI startups.
What we don't know yet
- What specific access controls or governance mechanisms Radical Numerics has implemented for Omnii beyond the CEO's public dual-use acknowledgment, and whether these will be disclosed.
- Whether Omnii's state-of-the-art benchmarks on causal regulatory variant identification have been independently replicated outside the company's own evaluations.
- How advisor Andrew Weber's defense-world connections will translate into formal government partnerships or regulatory engagement, and on what timeline.
Originally reported by SiliconAngle
Read the original article →Original headline: Radical Numerics Launches With $50M Seed to Build General Biological Intelligence Across DNA, RNA, and Proteins — Biosecurity Dual-Use Explicit